Monopar Therapeutics (MNPR) - Quarterly EPS earnings growth

Official company branding of Monopar Therapeutics Inc. (MNPR)

The prospects for Monopar Therapeutics (MNPR) are driven by the efficacy of radiopharmaceuticals, support from industry behemoths, and liquidity reserves. The quarterly EPS growth trajectory clearly demonstrates profit dynamics, with the -49.70 value serving as the baseline for the current metric. Monopar Therapeutics minimizes harmful emissions in accordance with ESG standards, while its market positions are protected by complex patents and stringent FDA control.

Monopar Therapeutics Inc. (MNPR) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/15/2026

Analytical breakdowns for Monopar Therapeutics

- market value and analyst target forecast:
Fundamental company analysis:monopartx.com, MNPR
Manufactured product of Monopar Corp

Quarterly EPS growth measures the rate of change in net income per share compared to the previous period. This model promptly captures the recovery of financial stability by reacting to any fluctuations in the bottom line. By analyzing the relative change in quarterly EPS, an investor can distinguish a short-term spike from systemic recovery. For Monopar Therapeutics (MNPR), this indicator reflects the impact of high operating expenses on capital. A positive trend will only become possible following the commercialization of radiopharmaceuticals.

Analysis of competing companies

Incyte Corporation (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HUTCHMED Corp|NUVB (nuvationbio.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months dayonebio.com (DAWN)|Year-over-year earnings per share growth for the last twelve months Inhibrx Corp (INBX)|IMAB - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Fennec Pharmaceuticals Inc FENC|Heron Therapeutics - Year-over-year earnings per share growth for the last twelve months|NVCT - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months coherus.com|CRBP: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Cardiff Oncology, Inc. CRDF|Year-over-year net earnings per share growth for the last 12 months BYSI|Earnings per share growth in annualized terms for the last twelve months BioAtla BCAB|Year-over-year net earnings per share growth for the last 12 months LIXT (Lixte Biotechnology)|CTXR (Citius Pharma) - Year-over-year earnings per one share growth for the last 12 months|Cellectar Biosciences - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months BLRX (BioLineRx)|Can-Fite BioPharma, Ltd. - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months APRE (aprea.com)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion (SLXN)|Year-over-year earnings per share growth for the last twelve months nucana.com|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth G1 Therapeutics Inc. (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Therapeutics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Portage Biotech Inc